News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

VinFuture Prize 2022 officially announces commencement of the pre-screening round

Vingroup

HANOI, VIETNAM - Media OutReach – 19 May 2022 - On May 18 th, 2022 – The commencement of VinFuture Pre-Screening Round has been officially announced. Honoring the theme of “Reshaping and Reviving”, the VinFuture Prize has received a total of 970 nominations, submited by prestigious scientists and institutions from more than 70 countries in six continents for its second award season. Under this year’s theme, nominations are centered around important research works and inventions that can help revive the post-pandemic world by solving humanity’s most pressing challenges related to health and the food supply, the environment and sustainable energy, as well as the application of technology in all aspects of life. Currently leading in number of nominators is Asia with 34.6% of the total accepted nominators, followed by the Americas with 29.8%, Europe with 16.2%, and Oceania with 7%. Notably this year, Africa has 12.4% of the nominators, six times higher than its share in 2021. In terms of quality, 584 out of 2618 nominators of the VinFuture Prize’s second season are individual nominators from the top 2% of most-cited researchers in the world, and 37.1% are from the world’s top 500 universities and research institutions, such as Harvard University, Stanford University, Yale University (U.S.A), University of Oxford (U.K.), Karolinska Institute (Sweden), Swiss Federal Institute of Technology, National University of Singapore, Tsinghua University (China), University of the Witwatersrand, Johannesburg (South Africa), Cairo University (Egypt), and many other leading universities and institutions globally. The VinFuture Pre-Screening round consists of a rigorous evaluation process based on the highest international standards in order to ensure scientific integrity, fairness, and transparency. The VinFuture Pre-Screening Committee will assess the nominations according to a set of core criteria, which includes the degree of scientific or technological advancement, the level of impact on people’s lives, as well as the project’s scale and sustainability. Dr. Lê Thái Hà, Managing Director of the VinFuture Prize, shared, “ Witnessing the consequences of two years of the COVID-19 pandemic, VinFuture recognizes its role in contributing to, and promoting, the global process of post-pandemic revival, aiming ultimately for sustainable development. With the theme of “Reshaping & Reviving”, the VinFuture Prize 2022 has gathered leading scientists from a variety of science and technology fields from across the world to increase the number of multi-dimensional perspectives in the nomination evaluation process. From this, we hope to find scientific solutions to the world’s pressing problems, and to simultaneously inspire and disseminate the great values that science and technology can bring in different sectors to new countries and territories, particularly in vulnerable areas. ” With the official commencement of the Pre-Screening round, the 2022 VinFuture Prize has announced three additional scientists to join its Scientific Councils this season. Professor Dan Kammen from the University of California, Berkeley (U.S.A), the former Science Envoy for the U.S. State Department, one of the world’s leading experts in the field of energy, will be officially joining the VinFuture Prize Council from 2022. The two other new professors joining the VinFuture Pre-Screening Council for the second season include Professor Quarraisha Abdool Karim – The 2016 L’Oréal-UNESCO for Women in Science Laureate, one of the Inaugural VinFuture Prize Laureates, and Professor Ermias Kebreab - the Director of the University of California, Davis World Food Center. Sharing his thoughts about his new role, Professor Dan Kammen said, “ I was especially impressed by VinFuture’s realistic message, as well as the mission of science and technology that has been disseminated through VinFuture’s humanitarian angle. I have high expectations for not only the quality, but also the applicability of the scientific nominations to real life. As a scientist who is dedicated to science for humanity, being able to participate in evaluating the nominations and choosing the scientific inventions and innovations to be the next Prize winners is a meaningful and enjoyable mission. ” The 2022 VinFuture Pre-Screening round takes place from May 18 th to late September, 2022 and aims to enable the Council to meticulously evaluate the most impactful and award-worthy works to proceed to the final round. VinFuture Prize Council: - Professor Sir Richard Henry Friend, FRS – University of Cambridge, UK, Millennium Technology Laureate in Physics 2010. - Professor Gérard Albert Mourou – École Polytechnique Palaiseau, France, Nobel Laureate in Physics 2018. - Professor Sir Konstantin (Kostya) S. Novoselov, FRS – University of Manchester, UK and National University of Singapore, Nobel Laureate in Physics 2010. - Professor Michael Eugene Porter – Harvard Business School, USA, creator of the theory "Competitive Advantage of Nations". - Professor Leslie Gabriel Valiant, FRS – Harvard University, USA, A.M. Turing Laureate 2010. - Dr. Padmanabhan Anandan – AI Matters Advisors LLC, USA. - Professor Jennifer Tour Chayes – University of California, Berkeley, USA. - Professor Pascale Cossart – Pasteur Institute of Paris, France. - Professor Van-Chi Dang – Ludwig Institute for Cancer Research, USA. - Dr. Xuedong David Huang – Microsoft, USA. - Professor Dan Kammen – University of California, Berkeley, USA. - Professor Ha-Van Vu – Yale University, USA and VinBigdata Institute, Vingroup, Vietnam. VinFuture Pre-Screening Committee: - Professor Thuc-Quyen Nguyen - University of California, Santa Barbara, USA. - Professor Albert P. Pisano - University of California, San Diego, USA. - Professor Mônica Alonso Cotta – Institute of Physics “Gleb Wataghin”, University of Campinas, Brazil. - Professor Ngoc-Minh Do - University of Illinois Urbana-Champaign, USA and VinUniversity, Vietnam. - Mr. Akihisa Kakimoto - Mitsubishi Chemical Corporation, Japan. - Prof. Quarraisha Abdool Karim - CAPRISA Center for the AIDS Programme of Research in South Africa - Professor Ermias Kebreab - University of California, Davis, USA. - Professor Duc-Thu Nguyen - Rutgers University, USA. - Professor Alta Schutte - University of New South Wales and The George Institute for Global Health, Australia. - Professor Molly Shoichet - University of Toronto, Canada. - Professor Vivian Yam – The University of Hong Kong, Hong Kong. About the VinFuture Foundation: The VinFuture Foundation, established on December 20th, 2020 on the occasion of International Human Solidarity Day, is an independent, not-for-profit foundation initiated by Mr. Phạm Nhật Vượng, and his wife, Madam Phạm Thu Hương. The mission and vision of the Foundation is to create meaningful changes in the everyday lives of millions of people in the world. The core activity of the Foundation is awarding the annual VinFuture Prize to technological innovations that have already contributed or have the potential to contribute to the betterment of life for millions of human beings globally. The VinFuture Prize consists of four prize categories, of which the Grand Prize – with a value of US$3 million – is one of the largest annual global prizes, and three additional Special Prizes, worth US$500,000 each, are dedicated to Female Innovator(s), Innovator(s) from Developing Country(ies), and Innovator(s) with Outstanding Achievements in Emerging Fields. In addition, the Foundation also conducts many activities to realize its mission, such as funding research, collaborating in academic development, and promoting STEM education. Contact Details Vingroup Media Contact v.nammh@vingroup.net

May 19, 2022 09:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Green Cubes Technology Expands Executive Team

Green Cubes Technology

Green Cubes Technology, a leader in electrification and clean, connected, cost-effective power solutions, today announced four significant executive appointments to its leadership team - Ken Gregory as Vice President of Supply Chain and Procurement, Alan Forster as Vice President of Sales for Americas, Rita Faunce as Vice President of Sales Operations and Customer Experience, and Rocio Castellanos as International Controller. These executives join Ken Johnson, who was appointed Chief Operating Officer (COO) last year. The team will provide leadership to sales, supply chain, operations, manufacturing, and customer support functions for continued growth within Motive (including Ground Support & Materials Handling), Stationary (Telecom & Data Center), and Mobile (Industrial Automation) Power market segments. “We’re very pleased to add so many talented professionals to Green Cubes’ executive team,” said Keith Washington, CEO of Green Cubes Technology. “This reflects the rapid growth of the company, and the leadership that each of these individuals bring to the company will help us continue to lead the charge to electrification.” Mr. Gregory has a history of success with enterprise operations and transformation, customer experience, supply chain and channel/alliance sales across enterprise and consumer Information Technology, Education and Learning organizations. He has driven sustainable cultural and digital transformations in highly matrixed organizations resulting in increased revenue, enhanced customer confidence, organizational capability, and employee engagement. He brings over 25 years of core supply chain experience gained at IBM supporting its enterprise computer hardware segments. Mr. Gregory’s most recent experiences were at Pearson, a global leader in learning and education where he oversaw customer service and digital operations transformation. Mr. Forster is responsible for managing and accelerating Green Cubes’ pipeline and revenue growth while developing its channel and sales enablement programs. In his recent role as Sales Director for the company’s Telecom and Data Center business unit (operating as Unipower), he helped rebuild sales and channel relationships, managed consistent quarterly growth, and increased sales channel coverage during the global pandemic. By working diligently with the Unipower team, he doubled bookings and revenue during a global supply chain and transportation slow down. Ms. Faunce directs Green Cubes’ sales operations teams globally, drives its customer experience strategy, and will facilitate ownership of customer experience excellence. She has vast experience managing global teams in sales operations, customer service, and customer satisfaction with success in delivering customer facing programs that foster a spirit of transparency, continuous improvement, and mutual accountability in customer relationships. Ms. Faunce will implement continuous improvement plans, leverage customer insights and data, and work across multiple departments to ensure team members and leadership are aware of and dedicated to the goals of continuously improving the customer experience. Ms. Castellanos joins Green Cubes as a key member of the global finance and accounting team. She is responsible for the internal and external financial reporting of all Green Cubes affiliated entities outside the U.S. In her role, she will support the entities in financial reporting topics and bridge the information to the U.S. headquarters. She will focus on continuous improvement of processes and deliverables to enhance financial performance visibility across the entities, as well as act as a strategic business advisor for International Operations. Ms. Castellanos brings over 20 years of experience and has worked for various companies including PwC, Swiss Life and Daniel Swarovski Corp. The expansion of Green Cubes’ executive team follows the company’s announcement last year that it added a second 36,000 square foot domestic facility in Kokomo, Indiana, and expanded its product lines for Motive and Stationary Power to support accelerated growth in Material Handling and Telecom markets. The Kokomo facility is currently increasing its manufacturing throughput and is expecting a 150% increase in Motive Power shipments in 2022, relative to 2021. Additionally, Green Cubes previously announced that it established two new facilities in Europe and a Technology Center in Zurich, Switzerland. About Green Cubes Technology Green Cubes Technology develops and manufactures safe and reliable electrification solutions that enable its OEM and enterprise customers to transition from Lead Acid and Internal Combustion Engine (ICE) power to Lithium-ion battery power. Green Cubes utilizes proven hardware and software platforms to build the most reliable Lithium power solutions in its industries. With a global footprint across six countries, Green Cubes has been producing innovative, high-performance and high-quality power solutions since 1986. More information at https://greencubes.com/. Contact Details Ray Young +1 512-633-6855 ray@razorsharppr.com Company Website https://greencubestech.com/

May 19, 2022 09:00 AM Eastern Daylight Time

Article thumbnail News Release

G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues

G Medical Innovations Holdings

Irvine, CA – May 18, 2022 – G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company”), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022. While the Company is still working on finalizing most of the revenue figures for the first quarter, the previously reported purchase orders received by the Company from McDade Products, LLC for 6 million co-branded LiveNow COVID-19 PCR Test Collection Kits (approximately $20 million in orders) have not materialized into revenues due to a slowdown of the pandemic in the US during the first quarter. Approximately $6 million of invoices have been submitted for payment, out of which $0.7 million has been received and another batch of claims of approximately $1 million is to be filed for payment. Further, the proposed budget for COVID-19 tests which has not yet been approved by the U.S. Congress creates further uncertainty as to revenue the Company expected to receive and recognize from sales of such tests in its testing centers. The Company plans to announce the final revenues numbers for the first quarter of 2022 as part of its financial results release for the first six months of 2022. The Biden administration has announced that it expects another outbreak of the pandemic as early as this fall with new variants and expects about 100 million patients, which we believe will increase the need for tests. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward looking statement in this press release when it is providing an update regarding its forecast for first quarter 2022 revenue in connection with the previously reported purchase orders, uncertainty of additional government funding for COVID-19 tests and the belief in an increased need for COVID-19 testing in the future. Because such actions deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of the Company could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on April 29, 2022, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

May 18, 2022 04:05 PM Eastern Daylight Time

Article thumbnail News Release

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). Kadimastem remains on track to submit IND to the FDA before the end of 2022 to begin a multicenter clinical trial of AstroRx® for ALS in 2023 in the U.S. As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services and Development Ltd. Hadasit is the technology transfer arm of Hadassah Medical Center. It is well known for its partnerships with international companies and research institutions, and its success with groundbreaking medical developments that fill unmet market needs. Under the terms of the agreement, Kadimastem’s astrocyte cells, which comprise AstroRx®, the company’s flagship product for ALS, will be tested for their therapeutic potential for MS using a unique animal model in Professor Tamir Ben-Hur’s laboratory at Hadassah Medical Center. Professor Ben-Hur is the Director of Brain Medicine at Hadassah Ein Kerem Medical Center and a pioneer and opinion leader in the field of clinical research in multiple sclerosis. If successful, the goal is to thereafter plan and conduct a clinical trial of AstroRx® for MS. "We are very excited about the expansion of the range of neurological diseases that astrocyte cells (AstroRx®) could be used to treat. The pre-clinical study that will be conducted at Professor Ben-Hur's laboratory is extraordinary. It’s a first-of-its-kind in the world to treat multiple sclerosis, " said Professor Michel Revel, Israel Prize Winner, Kadimastem Founder and Chief Scientist, and famous for his groundbreaking research that led to the development of the blockbuster drug Rabif for multiple sclerosis. Kadimastem CEO Asaf Shiloni said, “Expanding our R&D activity by conducting the ALS and the MS research in parallel enables us to provide maximum value for patients and investors alike. We are working diligently to move the ALS clinical program ahead. We also hope that AstroRx® will be the answer for the millions of MS patients for whom the usual method of treatment is ineffective. The use of AstroRx® cells, with their various mechanisms of action, may lead to an innovative regenerative treatment for the disease." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 a.shiloni@kadimastem.com Company Website https://www.kadimastem.com/

May 18, 2022 07:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

BreatheSuite Announces Latest Addition to Board of Directors

BreatheSuite

BreatheSuite Inc., a Canadian connected respiratory health company, today announced that Brad Fluegel officially joined the company’s Board of Directors. In his role, Fluegel will tap into his extensive digital health experience to provide feedback on how to support the company’s growth. “We welcome Brad to the BreatheSuite Board of Directors and look forward to leveraging his knowledge and experience in digital health as we continue to expand the BreatheSuite program,” said Brett Vokey, CEO of BreatheSuite. “We are excited to draw upon his background in commercial healthcare as we continue to work toward improving the lives of respiratory patients worldwide. Brad has exactly the experience we need to navigate the digital health ecosystem.” Before working as an advisor to healthcare organizations, entrepreneurs, and other participants in healthcare, Fluegel was most recently the senior vice president and chief healthcare commercial market development officer for Walgreen Co. based in Deerfield, Ill. He was responsible for all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Previously, he was chief strategy and business development officer for Walgreens, responsible for corporate strategy and business development. Prior to joining Walgreens, Fluegel served as executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint (now Anthem), among the nation’s largest health benefits companies. While at Wellpoint, Fluegel was responsible for long-term strategic planning, government affairs, corporate communications including public relations, corporate marketing, corporate development, international expansion, innovation and new business ventures. Fluegel was senior vice president of national accounts and vice president, enterprise strategy at Aetna, Inc. In this role, he led the national accounts business and was responsible for developing and executing on strategies that expanded Aetna’s position as a leader in the large employer market. “I’m excited to join BreatheSuite, as digital healthcare has always been a passion of mine because of its ability to improve people’s lives,” said Fluegel. “I look forward to using my experience to help BreatheSuite achieve its mission to provide better, more transparent care for all people with asthma or COPD.” Fluegel is well versed in the complexities of business and healthcare and is also a lecturer at the University of Pennsylvania’s Wharton School of Business. He earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a Bachelor of Arts in business administration from the University of Washington. He serves on the Board of Directors of MJHS Health System in New York City, Performant Financial Corporation and Premera Blue Cross, among others. He was also on the board of Fitbit before its sale to Google in early 2021. Fluegel’s appointment to BreatheSuite’s Board of Directors comes on the heels of BreatheSuite’s Chief Scientific Officer, Dr. Meshari F. Alwashmi, joining the Forbes Technology Council. The company also recently announced that it secured a spot on the inaugural Canadian Business New Innovators List. About BreatheSuite BreatheSuite is a Canadian connected health company empowering people with chronic respiratory conditions live longer, healthier lives. The BreatheSuite program incorporates a smart inhaler sensor designed to track and train proper inhaler usage, a BreatheSuite App to gamify getting Asthma & COPD under control, as well as health coaches to support patients wherever they are on their journey. BreatheSuite works with leading partners across North America to deliver better care to people with chronic respiratory conditions. For more information visit www.breathesuite.com or contact info@BreatheSuite.com. Follow us on Twitter, and LinkedIn Contact Details SVM Public Relations Erin O’Brien +1 401-490-9700 erin.obrien@svmpr.com Company Website https://www.breathesuite.com/

May 17, 2022 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Underline Science Closes Pre-Series A Round To Further Advance Scholarly Research With The Growth Of The Digital Video Library

Underline Science Inc

Most industries have progressed from paper to all forms of content; how is it that one of our most essential industries, science, is staying behind. This is something Underline's founder doesn't understand, and therefore he will change it with the launch of the Underline Digital Video Library (DVL). With a considerable track record, this multi-accomplished founder is now taking on the big publishers in a way that hasn't been seen before as a premier aggregator of streaming scientific conference lecture video content. Together with his team of industry leaders, Underline is aiming to transcend the industry into the 21st century. The mission of Underline is to improve researchers' access to quality scientific conference lecture video content. Historically, if you did not attend a scientific conference, you would miss out on all of the conference's lectures. Underline's DVL contains 26,000+ videos (Health Sciences, Life Sciences, Engineering, Technology, Social Sciences, and Humanities). The video content from the world's prestigious scientific societies and universities, like IEEE, Endocrine, AIP, lecturers from MIT, Harvard, Facebook, Google, etc. Each video is complete with abstract, English transcription, bio, picture of the author, and most importantly, a DOI (digital object identifier), which ensures that the video can be searched and discovered. Today, the company announced that it had raised a $2.5 million Pre-Series A round of funding, led by South Central Ventures and the Dutch Founders Fund. As a result, Mr. Jure Mikuz (South Central Ventures) and Mr. Laurens Groenendijk (Dutch Founders Fund) will join the Underline Board of Directors. "With this new round of funding, we'll be able to enhance the Underline DVL features and content greatly. Further to grow the team and expand our go-to-market strategy," Underline CEO and founder Alex Lazinica said in a press release. "We are looking forward to increasing our penetration into the library, government and corporate, institutional subscription market." South Central Ventures, who led the round, Managing Partner Jure Mikuz, said, “Underline’s mission resonates with us very well as they are addressing a global opportunity of creating a library of global scientific video content. I believe they will be successful by facilitating their excellent execution skills and deep industry knowledge. We are very excited to join Underline on this journey.” Founding Partner Laurens Groenendijk of The Dutch Founders Fund states, " We believe that if Underline Science manages to tap into the apparent possible network effects, it can quickly grow to be the dominant player in science content aggregation. We at Dutch Founders hope to see “underlining become a verb”. If anyone is going to do it, We know a seasoned entrepreneur like Alex is. “ Underline's business model is an annual subscription fee for unlimited access to the entire Digital Video Library for the subscribing institution's community. About Underline Science Underline is the premier virtual conference platform for events in science, medicine, academia, and other professional fields. Underline’s mission is to capture and disseminate scientific knowledge through video, making it globally accessible by enriching and preserving both virtual and hybrid conference content. Underline’s groundbreaking scientific Digital Video Library is providing new opportunities to access and expand the scientific record and accelerate scientific discovery. For more information, visit the Underline website and follow Underline on Twitter. About South Central Ventures South Central Ventures is a VC investor with the longest presence in the Balkans. Operating out of four offices – Ljubljana, Zagreb, Belgrade and Skopje – the team has invested in about 40 early stage tech companies and has been an integral part of the local start up communities. With a strong base of international investors, South Central Ventures is a go-to investor for regional tech companies competing in global markets. SCV’s portfolio companies include Cognism, Celtra, Agrivi, Orgnostic and AdScanner, among others. About Dutch Founders Fund DutchFounders is an early-stage venture capital fund from Amsterdam, started by a group of successful Dutch entrepreneurs like Laurens Groenendijk (Just Eat, Treatwell, Miinto, Hiber), Patrick Kerssemakers (fonQ), Bas Beerens (WeTransfer), Hidde Hoogcarspel (Spacebuzz) and Remco van Zanten ( Booking, Zalando, Vinted and BCG). The fund specialises in marketplaces and companies with strong network effects. Since its launch in 2018, the fund has successfully invested in 16 companies. This includes: YourCampus, Shypple, Vintage Cash Cow, Lumaly, Blanco, Nostics, Reveall, Veylinx, Wonderkind, Voicebooking, Fleks, Minimum, Caya, Winc Academy, Buildstream and Tracedock (exited to CM.com). The total fund has almost €100 million assets under management. DutchFounders is a committed partner of Techleap’s Fundright initiative. ### Contact Details Underline Science, Inc. Darrell W Gunter +1 973-454-3475 darrell@underline.io Company Website https://www.underline.io/

May 17, 2022 09:30 AM Eastern Daylight Time

Article thumbnail News Release

AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.

Appyea

AppYea (OTC: APYP) announced that its subsidiary SleepX, which focuses on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring – has signed new commercialization agreement for two additional patents by Ben-Gurion University. The new patented technology enables the innovative detection of sleep apnea and hypopnea through speech analysis using only a smartphone and with no physical contact. This is compared to traditional technologies that use physical sensors to detect apnea in overnight sleep labs. "In recent years we see a growing number of major players taking development efforts in the field of sleep monitoring and sleep apnea”, said Boris (Bary) Molchadsky, chairman & CEO of AppYea. “We are developing our own products that cater to this market while increasing our patent portfolio and examining synergistic technologies as part of our strategy to become a leading player in the sleep health market while also offering licensing agreements for leading smartphone manufacturers.” SleepX is a research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. SleepX focuses its activities on the development and commercialization of its flagship product SleepX PRO solution which is designed to diagnose sleep apnea using only a smartphone and with no physical contact. The company recently announced that it has applied to the Helsinki Committee for approval to begin its planned clinical trial on the SleepX PRO application. This trial is intended to take place at a hospital sleep lab as the first step toward applying for an FDA approval under the first-of-its-kind medical device category for “contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep”. As far as SleepX is aware, the global sleep apnea devices market size is valued at USD 3.7 billion as of 2020 with a 6.2% CAGR, reaching USD 6.1 billion by 2028, according to Grand View Research’s report. Safe Harbor and Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to our ability to raise capital needed to develop and market our products, the effectiveness of the Registration Statement, our ability to manage the business post acquisition, economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission. Contact Details Asaf Porat +1 800-674-3561 info@appyea.com Company Website http://www.appyea.com

May 16, 2022 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Funding update: Marquee tech founders and investors join Ultrahuman’s Series A

Ultrahuman

Several prolific tech investors and founders have come together to invest in Ultrahuman, a leading metabolic fitness platform that uses glucose biomarkers to help people optimize their lifestyle. Balaji Srinivasan (ex-Coinbase), Nithin Kamath (founder of Zerodha via Rainmatter) and Preethi Kasireddy (ex-a16z) along with several others have invested in Ultrahuman, the world’s most advanced metabolic fitness platform, in an undisclosed funding amount which will be in addition to their recent series A round. Others influential leaders include Groww founders (Harsh Jain, Lalit Keshre, Neeraj Singh and Ishan Bansal), Razorpay founder, Harshil Mathur and RazorpayX GM - Shashank Mehta, Akshay BD (founding team Uber India) and Tanmay Bhat (celebrity content creator and investor) as they support Ultrahuman, a metabolic fitness platform that helps people optimize their metabolism via real-time biomarkers like glucose in combination with HRV, sleep and activity insights. The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better. Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome, stress levels, time of the day, food ingredient quality, etc. Ultrahuman launched with Ultrahuman M1 - a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day using a continuous glucose monitoring device. It triggers timely personalized nudges to the user such as alerts to high glucose variability events leading to oxidative stress and suggestions to optimize it via lifestyle interventions. Nithin Kamath, founder of Zerodha, added: “A big part of living healthier is tracking your diet and eating right, but the problem is doing this accurately is tricky. The approach that Ultrahuman is taking to tackle this problem of improving metabolic fitness by using biomarkers is really interesting. We're excited to join Mohit and Vatsal on their journey.” Ultrahuman has raised over $25M to date. Existing investors include Alpha Wave, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of other angel investors including Tiger Global’s Scott Schleifer. “We’re super excited to welcome some of the world’s foremost founders, investors and biohackers to join our Series A round. The most inspiring aspect of this investment is that most of them are long term users of the platform as well and that strengthens our mission holistically”. said Mohit Kumar, Founder and CEO, Ultrahuman. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). During his training, he observed athletes train smartly via the usage of data, recovery tools and protocols. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. By using glucose and other biomarkers, Ultrahuman is helping people improve their energy levels, lose fat and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

May 12, 2022 06:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

CoorsTek Recognized as a US Best Managed Company

CoorsTek

CoorsTek is proud to announce it has been selected as a 2022 US Best Managed Company. Sponsored by Deloitte Private and The Wall Street Journal, the program recognizes outstanding U.S. private companies and the achievements of their management teams. The 2022 designees are U.S. private companies that have demonstrated excellence in strategic planning and execution, a commitment to their people and fostering a dynamic, resilient culture, as well as strong financials. This year’s designees continued to propel their businesses forward by prioritizing purpose, investing in their workforces, and demonstrating their commitment to diversity, equity and inclusion. “We are honored to be recognized as a best managed company again this year,” said Jonathan Coors, CEO of CoorsTek. “This award is a tribute to the dedication and resiliency of our CoorsTek team members across the globe over the past several years. It also speaks to the strong values that guide our daily activities and actions, and our focus on delivering essential products and services to the marketplace.” Applicants are evaluated and selected by a panel of external judges focused on assessing hallmarks of excellence in four key areas: strategy, ability to execute, corporate culture and governance/financial performance. They join a global ecosystem of honorees from more than 40 countries recognized by the Best Managed Companies program. About The Best Managed Companies Program The Best Managed Companies program is a mark of excellence for private companies. U.S. designees have revenues of at least $250 million. Hundreds of private companies around the world have competed for this designation in their respective countries through a rigorous and independent process that evaluates four key criteria in their management skills and practices — strategy, execution, culture and governance/financials. U.S. program sponsors are Deloitte Private and The Wall Street Journal. For more information, visit www.usbestmanagedcompanies.com. Please see www.deloitte.com/us/about for a detailed description of our legal structure. About CoorsTek Founded in 1910 and headquartered in Golden, Colorado, CoorsTek is a fifth-generation, family owned and operated global manufacturer of engineered ceramics. By utilizing over half of the world’s known elements in our material formulations, we deliver unique solutions to our diverse customer base by leveraging ceramic properties. With more than 30 facilities across three continents, five million square feet in manufacturing space, and more than 6,000 team members, we are the partner of choice in engineered ceramics. CoorsTek makes the world measurably better by providing customers with amazing solutions, serving customers in numerous industries including semiconductor, aerospace, automotive, medical, energy and many others around the world. For more information about the company and its products please visit our website at www.coorstek.com. Contact Details CoorsTek Nancy Fullerton +1 517-304-4695 nfullerton@coorstek.com Company Website https://www.coorstek.com

May 11, 2022 03:52 PM Eastern Daylight Time

1 ... 162163164165166 ... 226